ITOS insider transactions
iTeos Therapeutics Inc. (ITOS) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for ITOS
- Chief Operating Officer Call Matthew closing all direct ownership in the company (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Chief Executive Officer Detheux Michel closing all direct ownership in the company (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Director Lee David K4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Chief Medical Officer Feltquate David closing all direct ownership in the company (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Chief Scientific Officer Mcgrath Yvonne closing all direct ownership in the company (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Chief Financial Officer Gall Matthew closing all direct ownership in the company (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Director Hallal David4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Director Rhoads Ann D4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Chief Executive Officer Detheux Michel exercised 216,592 shares at a strike of $4.30 and sold $1,048,264 worth of shares (104,565 units at $10.02), increasing direct ownership by 13% to 153,903 units (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Chief Executive Officer Detheux Michel exercised 156,847 shares at a strike of $4.30 and sold $1,592,520 worth of shares (156,847 units at $10.15) (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Director Hallal David exercised 114,682 shares at a strike of $4.30 and sold $1,164,405 worth of shares (114,682 units at $10.15) (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Large owner Ecor1 Capital, Llc bought $38,685,562 worth of shares (4,958,978 units at $7.80) (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Former 10% Owner Gadicke Ansbert sold $8,317,364 worth of shares (1,031,931 units at $8.06) (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Former 10% Owner Mpm Bioventures 2018, L.P. sold $5,079,339 worth of shares (630,191 units at $8.06) (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Former 10% Owner Mpm Bioventures 2014, L.P. sold $5,079,339 worth of shares (630,191 units at $8.06) (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Director Van Hauwermeiren Timothy exercised 22,346 shares at a strike of $4.30 (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- New insider Ecor1 Capital, Llc claimed ownership of 5,730,000 shares (SEC Form 3)3 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Chief Financial Officer Gall Matthew was granted 24,000 shares, increasing direct ownership by 37% to 89,429 units (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Chief Scientific Officer Mcgrath Yvonne was granted 15,300 shares, increasing direct ownership by 49% to 46,300 units (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Chief Executive Officer Detheux Michel was granted 77,000 shares, increasing direct ownership by 131% to 135,903 units (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Chief Operating Officer Call Matthew was granted 24,000 shares, increasing direct ownership by 17% to 161,898 units (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Chief Medical Officer Feltquate David was granted 47,000 shares (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Chief Financial Officer Gall Matthew bought $38,635 worth of shares (5,000 units at $7.73), increasing direct ownership by 8% to 65,429 units (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Detheux Michel4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Feltquate David4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 3 filed by new insider Feltquate David3 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Director Ho Tony W4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Director Lee David K4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Director Van Hauwermeiren Timothy4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Director Davis Aaron I.4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Director Hallal David4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Director Desimone Jill4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Director Iannone Robert4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Director Rhoads Ann D4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Boxer Capital, Llc was granted 1,142,857 shares (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Ra Capital Management, L.P. disposed of 900,000 shares (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Gall Matthew4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Call Matthew4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Mcgrath Yvonne4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Detheux Michel4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Desimone Jill4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 3 filed by new insider Desimone Jill3 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Mcgrath Yvonne was granted 31,000 shares (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Call Matthew was granted 44,000 shares, increasing direct ownership by 47% to 137,898 units (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Gall Matthew was granted 41,000 shares, increasing direct ownership by 211% to 60,429 units (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Detheux Michel was granted 30,000 shares, increasing direct ownership by 104% to 58,903 units (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Lee David K4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 3 filed by new insider Lee David K3 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Gall Matthew bought $41,850 worth of shares (5,000 units at $8.37), increasing direct ownership by 35% to 19,429 units (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4: Boxer Capital, Llc sold $5,692,673 worth of shares (350,000 units at $16.26)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Van Hauwermeiren Timothy4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Rhoads Ann D4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Iannone Robert4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Ho Tony W4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Hallal David4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Dirocco Derek4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Davis Aaron I.4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Call Matthew4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Mcgrath Yvonne4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SEC Form 4 filed by Lager Joanne Jenkins4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)